



AFY 

REVERSED INNOVATION

WHAT

We find new indications for existing technologies.

WHY

We improve lives by addressing unmet medical needs.



01

A HISTORY OF
REVERSED
INNOVATION




02

INVESTMENT
OPPORTUNITY



03

INDICATIONS FOR
EXISTING
TECHNOLOGIES



04

PROTECTED
FROM
COMPETITION



A HISTORY OF REVERSED INNOVATION

MERGING DECADES OF TECHNOLOGY

AFYX is a Biopharmaceutical company with focus on reformulation and repurposing of pharmaceuticals.



2014: AFYX THERAPEUTICS

Development of a proprietary patented patch technology that sticks to wet surfaces

2015: LIONHEART PHARMACEUTICALS

Treatment of chronic and intermittent cluster headache.

2017: INPHENA PAIN & CANCER

Research, development and sales of repurposed existing pharmaceutical.

2024: MERGE: AFYX THERAPEUTICS

A history of Reversed Innovation. Biopharmaceutical company established through a merger of the above companies.

A 3D rendering of a DNA double helix structure, shown in a light blue color. It is positioned on the left side of the slide, with a background of soft, out-of-focus blue and white bokeh lights.

THE MEANING OF REVERSED INNOVATION

We find new indications for existing technologies.

Through our research, **we work relentlessly to improve lives by** addressing unmet medical needs.

As a leader in the biopharma area of **reversed innovation** we take an existing product or technology and use it to address a new or previously overlooked or unconsidered medical problem or condition.



DR. CLAUS J. MØLLER-SAN PEDRO
CEO

TRUSTED DEVELOPMENT

Dr. Claus J. Møller-San Pedro is the company CEO.

Dr. Møller co-founded and participated in securing successful IPOs of 3 companies in the BioPharma Industry:

OXiGENE Inc. (OTLC)

Genmab A/S (GMAB)

Y-mAbs Therapeutics, Inc. (YMAB)

BOARD OF DIRECTORS 2025



DR OLE BAADSGAARD

BOD Member, Chairman



DR CLAUD MØLLER-SAN PEDRO

CEO, BOD Member



MS PIA MØLLER-SAN PEDRO

BOD Member & SVP, Chief Operating Officer




MR SØREN KJÆR

Working BOD Member



OUR TECHNOLOGIES

PIPELINE



NIMORAZOLE

THE UNMET NEED:

Designed to increase the efficacy of radiation therapy by mimicking the effects of oxygen in the tumor and inducing **hypoxic tumor cells** to be more susceptible to radiation therapy.

- NIMORAZOLE
- ESKETAMINE
- RIVELIN
- MISOPROSTOL



HEAD & NECK CANCER

Blue Ocean market. No competition.



50,000 EU PATIENTS

Receive front line radiation treatment for SCCHN every year and would benefit from nimorazole.



DIAGNOSED

All patients are already diagnosed and scheduled for radiation.



+€250M/YEAR POTENTIAL IN EUROPE

Expected EU price of around €10.000 for full treatment in EU based on QALY gain.

ESKETAMINE

THE UNMET NEED:

An innovative approach to treat treatment of Cluster Headache.

- NIMARAZOLE
- ESKETAMINE
- RIVELIN
- MISOPROSTOL



SUICIDE HEADACHE

Improving daily living, quality of life and reduce the socioeconomic impact.



8 MILLION+ AFFECTED

60% of patients reported Complete or Moderate pain relief after 30 min.



NO ACCESS TO TREATMENTS

25% has no or low access to treatment.



+€500M/YEAR POTENTIAL in Europe alone.

RIVELIN

THE UNMET NEED:

- NIMARAZOLE
- ESKETAMINE
- RIVELIN
- MISOPROSTOL

RIVELIN PATCH TECHNOLOGY

THE UNMET NEED:

Multiple local diseases affect wet surfaces such as cavum oris (the mouth) and the vagina. Ordinary patches will not stick to such surfaces making precise and correct local application of pharmaceuticals very difficult. Our electrospun Rivelin Patch Technology is precisely addressing these problems and therefore has potential in a number of both immunological and malignant conditions.

MISOPROSTOL

THE UNMET NEED:

Misoprostol® is a 25-microgram misoprostol tablet developed and indicated for induction of labor.

- NIMARAZOLE
- ESKETAMINE
- RIVELIN
- MISOPROSTOL



OBSTERICS PRODUCT

Recommended by WHO in 2011 as first line option for induction of labor.



1,200,000 TREATMENTS in EU

One induction per patient per year.



ORAL ADMINISTRATION

Small oral tablet formulated with the recommended dose of misoprostol by WHO.



ANNUAL POTENTIAL

The global market potential is more than €300M.

SUMMARY

Powering Growth:

- ✓ Cash Flow
- ✓ Development
- ✓ Market Expansion

Proven cash flow generation:

Significant revenues from existing business with DKK 46M in 2025 and projected growth to DKK +200M by 2029

Two new drugs launching soon:

Misoprostol: EU registration expected April 2026, launch Q1 2027

Nimorazole: Regulatory filing Q1 2027, expected launch 2028

Large market opportunities:

Our products address markets with a potential of several hundred million € – e.g., Nimorazole alone has potential to generate sales of +€250M annually for Head & Neck Cancer treatment

Robust pipeline:

Multiple innovative products and expansion into new markets support continued growth

AFYX

THANK YOU!



afytx.com



+45 7174 7174



info@afytx.com